GLP-1RAs have been probable candidates for treating patients affected by COVID-19 infection, with or even without type 2 diabetes, and excellent antidiabetic (glucose-lowering) agents during the COVID-19 pandemic times. The glucagon-like peptide 1 (GLP-1) agonists act as a supporting agent and aim to decrease the symptoms' severity. Several technological advancements have increased, causing numerous modifications in the GLP-1RA drug or the formulations being developed.
Data Bridge Market Research shows that the Global Glucagon-Like Peptide 1 (GLP-1) Agonists Market was valued at 12.55 billion in 2021 and is likely to reach USD 20.15 billion by 2029, and will grow at a CAGR of 6.10% during the forecast period of 2022 to 2029.
" Increasing Technological Advancements Surge the Market Growth"
Pharmaceutical companies are making the latest innovations concerning formulations, combination therapies, improved bioavailability, and routes of administration. For instance, Novo Nordisk launched Rybelsus in the U.S. market for GLP-1 receptor agonists in 2019. It is the first once-weekly oral semaglutide-based tablet. Several clinical studies found it to be very effective compared to conventional treatment options for reducing HbA1C and mean change of body weight. Thus, this factor boosts market growth.
What restraints the growth of the Global Glucagon-Like Peptide 1 (GLP-1) Agonists Market?
Increasing Number of Product Failures"
Increasing product failures are anticipated to restrict the market's growth for GLP-1 receptor agonists. For instance, GlaxoSmithKline plc discontinued the sales and manufacturing of Tanzeum (albiglutide) in 2017 because of the product's decreasing sales and limited prescribing. The product was related to severe risks and limitations such as pancreatitis, diabetic ketoacidosis, and renal impairment. All these major factors impede the growth of the market.
Segmentation: Global Glucagon-Like Peptide 1 (GLP-1) Agonists Market
The global glucagon-like peptide 1 (GLP-1) agonists market is segmented on the basis of drugs, brand, route of administration and end users.
- On the basis of drugs, the glucagon-like peptide 1 (GLP-1) agonists market is segmented into exenatide, liraglutide, dulaglutide, lixisenatide.
- On the basis of brand, the glucagon-like peptide 1 (GLP-1) agonists market is segmented into byetta, bydureon, victoza, trulicity, lyxumia.
- On the basis of route of administration, the glucagon-like peptide 1 (GLP-1) agonists market is segmented into oral, parenteral, others.
- On the basis of end users, the glucagon-like peptide 1 (GLP-1) agonists market is segmented into hospitals, specialty clinics, others.
Regional Insights: North America is expected to dominate the Global Glucagon-Like Peptide 1 (GLP-1) Agonists Market
North America dominates the market due to the increase in healthcare. Additionally, the increasing research and development. Moreover, the incidence of major market players will further boost the growth of the region's glucagon-like peptide 1 (GLP-1) agonists market during the forecast period. North America has a high incidence of diabetes because of the sedentary lifestyle, and the market is anticipated to grow during the forecast period.
Asia-Pacific is expected to grow in 2022-2029 due to the increase in cases of diabetes and other related disorders. Furthermore, the increasing number of generic drugs is estimated to boost the growth of the region's glucagon-like peptide 1 (GLP-1) agonists market in the upcoming years. A high-end biopharmaceutical and pharmaceutical industry is also expected to contribute to this region's market growth over the upcoming years.
To know more about the study, visit, https://www.databridgemarketresearch.com/jp/reports/global-glucagon-like-peptide-1-glp-1-agonists-market
Recent Developments in the Global Glucagon-Like Peptide 1 (GLP-1) Agonists Market
- In 2022, the U.S. Food and Drug Administration (FDA approved Eli Lilly and Company's Mounjaro (tirzepatide) injection as a supplement to diet and exercise to increase glycemic control in adult patients with type 2 diabetes. A single molecule, Mounjaro is a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
- In 2021, AstraZeneca's Bydureon BCise (exenatide extended-release), the once-weekly injectable suspension, was approved in the U.S. for the treatment of type 2 diabetes (T2D) and to improve further glycemic control in pediatric patients aged 10 to 17 years.
The Prominent Key Players Operating in the Global Glucagon-Like Peptide 1 (GLP-1) Agonists Market Include:
- Lilly (U.S.)
- Novo Nordisk A/S (Denmark)
- AstraZeneca (U.S.)
- Sanofi (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
Above are the key players covered in the report, to know about more and exhaustive list of global glucagon-like peptide 1 (GLP-1) agonists market companies contact, https://www.databridgemarketresearch.com/jp/contact
Research Methodology: Global Glucagon-Like Peptide 1 (GLP-1) Agonists Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
